Chronic neuroinflammation in neurodegeneration partly reflects a failure of active resolution, not just excessive activation. SPMs (including Resolvin D1, Neuroprotectin D1, Maresin 1) activate receptors (ALX/FPR2, GPR32, LGR6) to promote microglial phagocytosis, limit cytokine production, and clear cellular debris. SPM levels are reduced in AD brains.
SPMs (resolvins, protectins, maresins) from omega-3s may promote inflammation resolution. Are resolution failures druggable?